MedTrace Logo

Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler

NCT00812682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 217

Last updated 2011-01-24

No results posted yet for this study

Summary

This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning.

Conditions

  • Perception of Physicians & Patients of AMD

Interventions

DRUG

Symbicort

Sponsors & Collaborators

Principal Investigators

  • Panagiotis Pontikis, MD · Medical & Regulatory Affairs Director, AstraZeneca Greece: 4

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-08-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812682 on ClinicalTrials.gov